Structure‐Based Macrocyclization Yields Hepatitis C Virus NS5B Inhibitors with Improved Binding Affinities and Pharmacokinetic Properties
- 30 March 2012
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 51 (19) , 4637-4640
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical spaceMedChemComm, 2011
- Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug DiscoveryJournal of Medicinal Chemistry, 2011
- Discovery of (7R)-14-Cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a Potent and Orally Bioavailable Finger-Loop Inhibitor of the Hepatitis C Virus NS5B PolymeraseJournal of Medicinal Chemistry, 2010
- N-Acetamideindolecarboxylic acid allosteric ‘finger-loop’ inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studiesBioorganic & Medicinal Chemistry Letters, 2010
- Discovery of pentacyclic compounds as potent inhibitors of hepatitis C virus NS5B RNA polymeraseBioorganic & Medicinal Chemistry Letters, 2009
- Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymeraseBioorganic & Medicinal Chemistry Letters, 2009
- The exploration of macrocycles for drug discovery — an underexploited structural classNature Reviews Drug Discovery, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffoldsBioorganic & Medicinal Chemistry Letters, 2006
- Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymeraseXenobiotica, 2005